Ttp

certo a prospettive nn e' messa male

il dilemma rimane sempre quello e cioe' dove puo' arrivare?

a saperlo uno metterebbe uno stop largo e viaaaa...
 
cervellofine ha scritto:
certo a prospettive nn e' messa male

il dilemma rimane sempre quello e cioe' dove puo' arrivare?

a saperlo uno metterebbe uno stop largo e viaaaa...

forse 20$ nel 2009,,,
prima non so,,
 
mha

certo primo supporto 3 , se ci arriva e tiene si puo' provare

magari con una prima trance :) :)
 
Ultima modifica:
Ciao Paolo :) allo stato attuale i 3$ potrebbero essere pochi come molti, bisogna attendere........

ciao Olandese ;)

 
il problema e che difficilmente incasseranno royalties per l'iloperidone,,
prima del lancio previsto nel Q1 del 2009,,

quindi per raccattare fondi potrebbero piazzare azioni nel frattempo,,,

ola

P
 
Ultima modifica:
Paolino967 ha scritto:
il problema e che difficilmente incasseranno royalties per l'iloperidone,,
prima del lancio previsto nel Q1 del 2009,,

quindi per raccattare fondi potrebbero piazzare azioni nel frattempo,,,

ola

P

concordo perche al di là della pipeline ci vogliono fondi per sostenersi sopratutto se ancora non si è profittevoli.......
 
l'iloperidone e superiore a Geodon della Pf,,
che ha fatturato 589 milioni nel 2005 con questo farmaco,,.

Ammettiamo che Vanda arrivi a 600 milioni nel 2010,
questo significherebbe che Titan incasserebbe,,
200x0,08
400x0,1

ovvero 56 milioni di royalties.

Se iloperidone diventasse un block buster da 1 mil di fatturato,,
la cifra raddoppierebbe

Il problema e che il lancio e parecchio in la,,,
comuque se il sentiment nel 2007 fosse buono per via della approvazione a fine 07 del farmaco da parte della fda,,
penso che il titolo potrebbe arrivare sui 6-7$,,,nel 2007

poi il prezzo potrebbe consolidare sugli stessi livelli nel 2008,,
e spiccare il volo nel 2009.

Il trial e un late fase III e i risultati sono buoni,,,

Ora mi riguardo cosa dicono sul loro sito web



ola

P
 
siamo sui 3,1 oggi,,
vediamo cosa succede da qui a fine anno,,
 
oggi tocca la base della candela,,,
mezza tranche la metto via, giusto per esserci,,
solo long, non la trado,,

P
 
area 3$ ha tenuto al momento,,,

c´e´una discreta vivacita nel farmaceutico (small e medim cap) negli ultimi tempi,,

ola

P
 
nessuna novita,,
le medie salicchiano,,,
prossimo aggiornamento a meta gennaio,,,
 

Allegati

  • ttp 6 months.png
    ttp 6 months.png
    24,7 KB · Visite: 184
Paolino967 ha scritto:
il problema e che difficilmente incasseranno royalties per l'iloperidone,,
prima del lancio previsto nel Q1 del 2009,,

quindi per raccattare fondi potrebbero piazzare azioni nel frattempo,,,

ola

P

furbacchioni eh :D:D:D

Titan Pharmaceuticals files $50 mln stock shelf
Thu Feb 8, 2007 2:56pm ET

Company News:
Titan Pharmaceuticals files $50 mln stock shelf
UPDATE 4-Vanda shares up 69 pct on schizophrenia drug data
More Company News... Email This Article | Print This Article | Reprints [-] Text [+]
WASHINGTON, Feb 8 (Reuters) - Biopharmaceutical company Titan Pharmaceuticals Inc. (TTP.A: Quote, Profile , Research) said on Thursday it may periodically sell up to $50 million in common and preferred stock.

The company plans to use the proceeds for general corporate purposes, research and development, preclinical studies and clinical trials, and for equipping facilities.

Under a shelf registration filed with the U.S. Securities and Exchange Commission, a company may sell securities in one or more separate offerings with the size, price and terms to be determined at the time of sale.
 
Titan Pharmaceuticals, Inc. (AMEX: TTP) is a biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system disorders, cardiovascular disease, bone disease and other disorders. Titan's products in development utilize novel technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes partnerships with government institutions and other leading pharmaceutical development companies. Titan's product development pipeline includes five products in clinical testing.


Iloperidone

In December 2006, the final planned Phase III clinical study for iloperidone was completed. The results from this clinical trial evaluating iloperidone in patients with schizophrenia demonstrated statistically significant improvement compared to placebo on the Positive and Negative Symptom Scale (PANSS), the trial's primary endpoint. Vanda Pharmaceuticals, Inc., the sub-licensee of iloperidone, is funding the product's development. Vanda plans to file an NDA for iloperidone with the FDA by the end of 2007.

Probuphine

In October 2006, Titan initiated a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in opioid dependence. This study will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid dependence over 24 weeks of treatment. The Phase III program is also anticipated to include additional clinical studies to be conducted later in the U.S. and Europe. We continue to have discussions with the FDA relating to finalizing the Probuphine development program.

Spheramine

Enrollment is continuing in the 68 patient, double-blind, placebo controlled Phase IIb clinical study of Spheramine® in the treatment of Parkinson's disease. In accordance with our agreement with Bayer Schering Pharma AG, Germany (Bayer Schering), our corporate partner for the development of Spheramine, the Investigational New Drug application (IND) held by Titan with the FDA was transferred to Bayer Schering. The Spheramine program continues to be jointly managed by Titan and Bayer Schering through a previously established Joint Development Committee. To date, 65 patients have been treated and the results from this study are expected to be available in 2008.

DITPA

We are currently evaluating DITPA as a potential treatment for hyperlipidemia in a Phase II, randomized, double-blind, placebo-controlled, investigator sponsored study at the Johns Hopkins Medical Institutions in Baltimore. The study includes individuals receiving standard lipid-lowering therapy, whose LDL cholesterol levels are above National Cholesterol Education Program (NCEP) guidelines. The study will evaluate DITPA as a cholesterol lowering agent in combination with standard therapy.

The NCEP has recently updated its guidelines recommending lower target LDL cholesterol levels, based upon recent data indicating that further lowering of target LDL cholesterol level guidelines may be important in reducing the incidence of heart disease and stroke.

Gallium maltolate

We are developing a new formulation of gallium maltolate with potentially improved bioavailability, and plan to use this new formulation in any future clinical development of gallium maltolate.
 

Allegati

  • ScreenHunter_42.gif
    ScreenHunter_42.gif
    21,3 KB · Visite: 72
Ultima modifica:
,,,occhio a questa, dal movimento degli ultimi giorni, lunedì potrebbe fare moooooooolto bene,,,,,, :yes: :p

Last Trade: 2.42

Change: 0.26 (12.04%)

Prev Close: 2.16

Volume: 663,800
Avg Vol (3m): 224,047
Market Cap: 107.63M
 
Indietro